Evidence map›Paper›PMID 28442369›Full record

ArticlePharmacology, biochemistry, and behavior2017

Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABA

J M Witkin, R Cerne, M Wakulchik, J S, S D Gleason, T M Jones, G Li, L A Arnold, J-X Li, J M Schkeryantz and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. 8-Substituted Triazolobenzodiazepines:Frontiers in pharmacology · 2021
    Article
  6. The Positive Allosteric Modulator ofThe Journal of pharmacology and experimental therapeutics · 2020
    Article
  7. The α2,3-selective potentiator of GABAPharmacology, biochemistry, and behavior · 2019
    Article
  8. Article
  9. Synthesis of chiral GABAARKIVOC : free online journal of organic chemistry
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

J M WitkinLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, United States. Electronic address: jwitkin@lilly.com.
R CerneLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, United States.
M WakulchikLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, United States.
J SLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, United States.
S D GleasonLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, United States.
T M JonesLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, United States.
G LiDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, United States.
L A ArnoldDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, United States.
J-X LiDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, United States.
J M SchkeryantzLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, United States.
K R MethukuDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, United States.
J M CookDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, United States.
M M PoeDepartment of Chemistry & Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI, United States.
Eli Lilly (United States) · USUniversity of Wisconsin–Milwaukee · USUniversity at Buffalo, State University of New York · US

Funding

SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDSR01MH046851 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 1991 to 2010
$4.4M
Development of new drugs for asthma by targeting GABA(A) receptors in the lungR01HL118561 · NHLBI · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2014 to 2017
$2.0M
Design of New Therapeutic Agents to Treat SchizophreniaR01MH096463 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2013 to 2017
$1.9M
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3M
NHLBI NIH HHS R01 HL118561NIMH NIH HHS R01 MH046851NIMH NIH HHS R01 MH096463NINDS NIH HHS R01 NS076517
6 · The paper itself

Abstract

Positive allosteric modulators of GABA

Indexed as

AnimalsAnti-Anxiety AgentsAnxietyBenzodiazepinesDose-Response Relationship, DrugDrug Evaluation, PreclinicalGABA-A Receptor AgonistsHEK293 CellsHumansMaleRatsRats, Sprague-DawleyReceptors, GABA-AAnti-Anxiety AgentsBenzodiazepinesBz-423GABA-A Receptor AgonistsGabra2 protein, ratGabra3 protein, ratReceptors, GABA-A

Identifiers

PMID28442369
PMCPMC5519285
OpenAlexW2607138535

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.